Innovation
Developing tests to characterize pathologies is the common thread of Genexpath’s activity. Our products have been implemented to best respond to the problems of professionals who contribute to the diagnosis, research and treatment of patients.
Those tests are based on an innovative technique which has been the subject of several publications in scientific journals with a high impact factor. The technique has already been well tested.
These tests are carried out on mRNA for which the quantity of RNA necessary is very low to obtain robust results. For example, in the context of sarcomas, a less invasive needle biopsy is sufficient to allow the detection of fusion transcripts.
Genexpath tests allow much faster and much cheaper analysis of pathologies than other methods, whether traditional or innovative.
Characterization tests
Genexpath offers two innovative tests to characterise tumours : LymphoSign test, SarcomaFusion test.
These solutions combine an in vitro test (RT-MLPSeq) and bioinformatics analysis after NGS sequencing.
Our tests are specially designed to analyze difficult or small quantity samples. Their simple and rapid protocol allows easy integration into laboratories, without requiring specific equipment. An NGS sequencer and standard laboratory equipment are sufficient.
Assays can be sequenced simultaneously with other libraries and require only 100,000 reads per sample. This feature makes it possible to considerably reduce costs and delays: it is no longer necessary to wait for a sufficient number of samples before starting sequencing or to use a sequencer exclusively for these analyses.
After sequencing, the RT-MIS software facilitates the interpretation of the results. Its use is intuitive, fast and without local installation. It carries out demultiplexing and counting of raw and relative data according to the test used. It provides detailed and usable results, while guaranteeing optimal security thanks to hosting on a certified HDS (Health Data Hosting) server.
These tests are the result of research work carried out within the INSERM U1245 unit at the Center Henri Becquerel in Rouen, with which Genexpath collaborates closely. Now available at international scale, they offer practitioners or researchers a powerful and accessible characterization solution.
LymphoSign test
The LymphoSign test offers precise measurement of the expression signature of more than 130 genes of interest
in order to characterize non-Hodgkin lymphomas according to the WHO classification (using artificial intelligence).
Learn more
SarcomaFusion test
The SarcomaFusion test can detect up to 140 different fusion transcripts involved in sarcomas.
Learn more
Our panels
Genexpath offers panel solutions to precisely measure gene expression.
CustomPanel solution, offers the possibility of analyzing the expression of genes selected by users according to their needs.
ThemaPanels solutions, are designed by Genexpath around specific themes, based on preselected genes.
These solutions are based on technology RT-MLPSeq and integrate bioinformatics analyses.
Like our characterization tests, gene panels can be sequenced simultaneously with other libraries and require only 100,000 reads per sample.
This characteristic significantly reduces costs and lead times.
After sequencing, the RT-MIS software facilitates the interpretation of the results. Its use is intuitive, fast and without local installation. It carries out demultiplexing and counting of raw and relative data according to the test used. It provides detailed and usable results, while guaranteeing optimal security thanks to hosting on a certified HDS (Health Data Hosting) server.
ThemaPanels
Find here the different thematic panels developed by Genexpath, such as our panel, HumInflammation, thematic panel on inflammation in humans.
Learn more
CustomPanel
The CustomPanel service allows you to evaluate the mRNA expression level of markers of interest that you choose.
Learn more
Software solution
GenerateReports is a bioinformatic platform for analyzing raw next-generation sequencing data from primary to tertiary analysis. It makes it possible to study the results of a sample, a cohort or even to follow them over time.
GenerateReports is also integrated into the platform FrenchConnect developed byInstitut Carnot Calyma platform that aims to harmonize and evaluate the performance of circulating free tumor DNA (ctDNA) analysis in the plasma of lymphoma patients.
GenerateReports
Next-generation sequencing raw data analysis platform.
Learn more